Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Reid: Ban this sport before boxing
CNBC’s John Harwood asks Harry Reid about his boxing days.
Brexit delay puts Bank of England in a really tight spot, expert says
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Hetal Mehta, senior European economist at Legal & General Investment Management, discusses the impact of Brexit on U.K. policymakers. 02:07 Thu, May 2 20198:08 AM EDT
Options Traders prepare for huge slate of earnings
Mike Khouw, Optimize Advisors president, joins the Options Action traders to discuss Tesla.
American Century’s Rich Weiss still bearish on the market, says it’s difficult to see strong upside
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell Rich Weiss, American Century Investments CIO, joins ‘Closing Bell’ to offer his bearish take on the market. 05:23 Wed, Jan 10 20244:54 PM EST
Watch CNBC’s full interview with Trivariate Research’s Adam Parker and Wealth Enhancement’s Nicole Webb
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Trivariate Research CEO Adam Parker and Nicole Webb, senior vice president and financial advisor at Wealth Enhancement Group, join ‘Closing Bell’ to discuss their market outlook for 2024, expectations from the Fed, and more. 19:36 Tue, Jan 9 20243:35 PM EST
Citi’s restructuring will work this time, says Wells Fargo’s Mike Mayo
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell Mike Mayo, Wells Fargo bank analyst, joins ‘Closing Bell’ to discuss Citi’s Q4 warning, his bank earning predictions, and more. 05:16 7 minutes ago
